As of November 6, 2026, Stoke Therapeutics, Inc. is a publicly traded company (Nasdaq: STOK); its largest reported holder is RTW Investments, with 9.9% on Schedule 13G/A of May 15, 2026, then Fidelity (FMR) (7.5%) (Schedule 13G/A, May 15, 2026).
Is this your company?
About to sign with, pay or invest in Stoke Therapeutics, Inc.? See the free Snapshot first.
Free to see. No signup.
Is Stoke Therapeutics, Inc. a real, registered company?
- Stoke Therapeutics, Inc. files with the SEC under CIK 1623526 (its SEC filings).
- Its shares are listed under the ticker STOK on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in Bedford, Massachusetts, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under STOKE THERAPEUTICS INC in our court records and SEC 8-K records (as of 2026-11-06).
- Leadership changes: the latest reported is G. Clare Kahn, Director (Form 8-K filed 2026-04-07). Check you are dealing with the people now in charge.
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Fidelity (FMR) (filed 2026-11-05).
Who are Stoke Therapeutics, Inc.'s owners and officers?
Stoke Therapeutics, Inc.: incorporated in Delaware; business address in Bedford, Massachusetts; industry Pharmaceutical Preparations (Schedule 13G/A, 2026-11-05).
| Report | Holder | Share |
|---|---|---|
| Schedule 13G/A, 2026-11-05 | Fmr LLC | 7.5% |
| Schedule 13G, 2026-09-30 | Bvf Partners L P/Il | 5.6% |
| Schedule 13G/A, 2026-08-14 | Lynx1 Capital Management LP | 6.5% |
| Schedule 13G/A, 2026-08-12 | The Toronto-Dominion Bank | 4.9% |
| Schedule 13G/A, 2026-08-06 | Fmr LLC | 8.5% |
| Schedule 13G/A, 2026-05-18 | Lynx1 Capital Management LP | 8.1% |
| Schedule 13G/A, 2026-05-15 | Rtw Investments, LP | 9.9% |
| Schedule 13G/A, 2026-05-15 | The Toronto-Dominion Bank | 5.4% |
| Schedule 13G, 2026-05-15 | Wellington Management Group LLP | 5.2% |
| Schedule 13G/A, 2026-05-15 | Redmile Group, LLC | 6.7% |
| Schedule 13G/A, 2026-05-15 | Lynx1 Capital Management LP | 7% |
| Schedule 13G/A, 2026-03-27 | The Vanguard Group | 0% |
Questions about who owns Stoke Therapeutics, Inc.
Who owns Stoke Therapeutics, Inc.?
On this page, 6 holders' latest ownership filings report 5% or more of Stoke Therapeutics, Inc.: Rtw Investments, LP (9.9%, Schedule 13G/A, filed 2026-05-15), Fmr LLC (7.5%, Schedule 13G/A, filed 2026-11-05), Redmile Group, LLC (6.7%, Schedule 13G/A, filed 2026-05-15), Lynx1 Capital Management LP (6.5%, Schedule 13G/A, filed 2026-08-14) and Bvf Partners L P/Il (5.6%, Schedule 13G, filed 2026-09-30); 1 more is listed above.
Who are the largest shareholders of Stoke Therapeutics, Inc.?
By the share each holder's latest filing reports, the largest holders of Stoke Therapeutics, Inc. on this page are Rtw Investments, LP (9.9%), Fmr LLC (7.5%) and Redmile Group, LLC (6.7%).
When did Rtw Investments, LP buy into Stoke Therapeutics, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Rtw Investments, LP on this page is the Schedule 13G/A, filed 2026-05-15, reporting 9.9%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 12 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Stoke Therapeutics, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Stoke Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Stoke Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
16 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
| Filed | Person | Role | Change | Effective |
|---|---|---|---|---|
| Form 8-K, 2026-04-07 | G. Clare Kahn | Director | appointed |
Which insiders own Stoke Therapeutics, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- Blue Horizon Enterprise Ltd, a 10% owner: 3,906,181 shares (6.0% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2025-06-06).
- Ezbon International Ltd, a 10% owner: 3,906,181 shares (6.0% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2025-06-06).
- Skorpios Trust, a 10% owner: 3,906,181 shares (6.0% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2025-06-06).
- Montrago Trustees Ltd, a 10% owner: 3,906,181 shares (6.0% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2025-06-06).
- , a director: 283,302 shares (0.43% of shares outstanding) (Form 4, 2026-03-12).
Shares outstanding: 65,406,268 as of 2026-10-30, from the company's latest SEC cover page.
How much has Stoke Therapeutics, Inc. raised?
No fundraising or offering filing from Stoke Therapeutics, Inc. is on file with us.
Keep reading
More on Stoke Therapeutics, Inc. and the records around it.
Stoke Therapeutics, Inc. elsewhere on the record
- 5%+ stake filings Nov 2026
- Leadership changes Sep 2026
Companies that share a holder
- Cowen Financial Products LLC also filed stake reports on 1 other company: UroGen Pharma Ltd. (Nov 2025)
- The Toronto-Dominion Bank also filed stake reports on 5 other companies: eBay Inc. (Aug 2026), UroGen Pharma Ltd. (Aug 2026), Immatics N.V. (May 2026)
- Lynx1 Capital Management LP also filed stake reports on 11 other companies: C4 Therapeutics, Inc. (Aug 2026), GH Research PLC (Aug 2026), iBio, Inc. (Aug 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/stoke-therapeutics